

NON-RENOUNCEABLE ENTITLEMENT OFFER DESPATCH OF OFFER DOCUMENT

Perth, Australia, 26 June 2019: Australian medical technology company BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**), is pleased to advise that the Offer Document and Entitlement and Acceptance Form in connection with its non-renounceable Entitlement Issue was despatched to Eligible Shareholders today.

Any enquiries regarding the Entitlement Offer should be directed to the Company Secretary on +618 93819550.

P Collinson

Company Secretary

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian medical technology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1 owns a proprietary tumour marker platform with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of breast, ovarian and lung cancers. BARD1's vision is to detect cancer early and save lives. For more information on BARD1, see www.bard1.com.